key: cord-1045924-vr0y7ty4
authors: Netea, Mihai G.; Domínguez-Andrés, Jorge; van de Veerdonk, Frank L.; van Crevel, Reinout; Pulendran, Bali; van der Meer, Jos W.M.
title: Natural resistance against infections: focus on COVID-19
date: 2021-12-07
journal: Trends Immunol
DOI: 10.1016/j.it.2021.12.001
sha: 3fa9e6273ddeb2014f10215e64eafa6501f2e79f
doc_id: 1045924
cord_uid: vr0y7ty4

Not all individuals exposed to a pathogen will develop illness: some are naturally resistant; others will develop an asymptomatic infection. Epidemiological studies suggest that similar variability in susceptibility exists against SARS-CoV-2 infections. We propose that natural resistance is part of disease history in some individuals exposed to this new coronavirus. Epidemiological arguments for natural resistance to SARS-CoV-2 are the lower seropositivity of children compared to adults, studies on closed environments of ships with outbreaks, and prevalence studies in some developing countries. Potential mechanisms of natural resistance include host genetic variants, viral interference, cross-protective natural antibodies, T-cell immunity, and highly effective innate immune responses. A better understanding of natural resistance can help advance preventive and therapeutic measures against infections for improved preparedness against potential future pandemics.

Not all individuals encountering a pathogen will develop an ensuing disease. Most pathogenic microorganisms in nature do not infect humans, but are specific to other hosts. By contrast, some individuals are fully resistant to infection with certain pathogens. Should an infection occur, the severity of the disease greatly varies between patients, which is believed to be due to genetic, non-genetic (age, diet, life style), and environmental factors. The capacity of a pathogen to cause an epidemic or even a pandemic, greatly depends on the susceptibility of the host to infection, mode of transmission of the infectious pathogen, and severity of the disease. In the current piece, we focus on the immunological mechanisms of natural resistance to pathogens.

A strong argument for the relevance of immunological mechanisms for the natural resistance to pathogens is given by the type of immune response elicited in humans versus other species against an infection: for example, bats, unlike humans, respond to coronavirus infection with high production of interferons (IFNs) and low inflammation, which is a likely mechanism inducing a high level of tolerance against such infections [1] (Box 1). By contrast, humans are known to respond with a strong inflammatory reaction during many viral infections such as those caused by influenza virus or coronaviruses [2, 3] .

The variability in the capacity of pathogens to cause infection is not only restricted to inter-species differences, but also to immunological variation between individuals within one population. Why do some people not develop illness? Are there interindividual mechanisms similar to those explaining why certain animal species are naturally resistant to a particular infection? To understand this, we must conceptually demarcate two situations: natural resistance from asymptomatic infection. These processes are mediated by different mechanisms; namely, genetically vs innate immune mediated for natural resistance, versus potentially induced adaptive immunity for asymptomatic infections (Box 2). maybe even the majority of SARS-CoV-2-infected subjects, do not develop any clinical symptoms [5] . Here, we briefly review the extensive knowledge on natural resistance in humans against infections and outline the epidemiological and immunological arguments that support the presence of natural resistance to SARS-CoV-2 infection in humans. We also propose that among various types of infections, SARS-CoV2 is no exception in that individuals exist that are naturally resistant to infection.

Natural resistance against pathogens has been described for many infections, including some of the most severe and widespread infections in human populations. Exposure to Mycobacterium tuberculosis can lead to latent (asymptomatic) infection, which can progress to active tuberculosis disease. However, some individuals, even when heavily exposed to a contagious tuberculosis patient, will not develop latent infection. This phenotype has been termed 'early clearance' [6] . Malaria is another well-known example of a human Plasmodium sp. infection in which natural resistance has been described [7] . While malaria exerts strong evolutionary pressure on humans [8] , a multitude of studies published more than half a century ago have shown that certain segments of the population are resistant to developing malaria. This resistance is associated with the presence of sickle cell disease mutations in hemoglobin-B or C genes [9] , thalassemias [10] , or the presence of the Duffy antigen receptor gene (DARC) in erythrocytes [11] . Genetic polymorphisms inducing natural resistance have also been described in HIV-1 infection, which in evolutionary terms, represents a relatively recent infection. Some 25 years ago, approximately 10% of sex workers in Kenya that were highly exposed to HIV-1 were reported to remain uninfected after 3 years of follow-up [12] . It was later found that this was caused by genetic defects in the CCR5 entry receptor on CD4 + T-cells: indeed, the CCR5-Δ32 deletion mutation eliminates this HIV-1 co-receptor on lymphocytes, and has provided robust protection against HIV-1 infection and AIDS [13] .

These studies present a picture in which the disease history of any individual can greatly vary depending of the variability of his or her susceptibility to disease: one J o u r n a l P r e -p r o o f Journal Pre-proof person can be naturally resistant to an infection, another can be infected but remain asymptomatic or exhibit mild symptoms, while another person can become severely ill ( Figure 1 ). We thus propose that natural resistance is an important component of disease history in most human infections. There is no reason to believe that this would be different for SARS-CoV-2 infection.

Similar to other viral infections such as HIV-1, SARS-CoV-1 or MERS, human infection with SARS-CoV-2 is evidently recent: it has caused a pandemic since the end of 2019.

The high morbidity and mortality burden, with tens of millions infected and several million individuals perishing from the disease, is mainly due to the absence of a protective immunological memory to the disease; indeed, because of the short time period in which the disease has been present in the global population, evolutionary pressure to presumably increase resistance to infection and/or disease is yet to occur.

However, the mortality due to COVID-19 is highly prevalent in individuals that have passed the reproductive age, and because of that, it is likely to result in a faint, if any, evolutionary pressure. Nevertheless, evidence is starting to accumulate suggesting that not everyone is equally susceptible to SARS-CoV2 infection [14] , and some of us may even be naturally resistant ( Figure 2 ).

The first likely mechanism that might mediate natural resistance agianst SARS-CoV-2 can be considered as being genetically-mediated: low expression of the viral receptor ACE2 might be associated with resistance to disease, and such a potential mechanism has been suggested for children [15] , although this possibility remains to be rigorously tested [16] . Moreover, while genetic variation is important and might explain up to 30-50% of inter-individual immune variations (as revealed by functional genomics studies) [17] , environmental factors are also important and might have more of an impact later in life [18] .

A strong argument for the presence of naturally resistant individuals to SARS-CoV2 infections in the population comes from the strong age dependency in the epidemiology of COVID-19 [19] . Specifically, the low severity of COVID-19 in children is J o u r n a l P r e -p r o o f Journal Pre-proof a fact [20] , but a meta-analysis of epidemiological surveys of specific anti-SARS-CoV-2 antibodies in serum also show lower anti-SARS-CoV-2 antibody titers in children and adolescents compared to adults, even if the former co-habitate with adults in the same environment, and hence, presumably receive equal exposure to the virus [21] . In a large survey in southwest Germany, children aged 1 to 10 years presented a three-fold lower SARS-CoV2 seroprevalence of antibodies compared to their parents [22] , while the SARS-CoV2 seroprevalence of children (5 months to 4.4 years) versus adults in a day care environment in France was 4.3% vs 7.7%, respectively [23] . Thus, at least some children seem to be able to repel the infection without the need to strongly engage adaptive immunity, either through resistance to infection (perhaps low expression of SARS-CoV-2 receptors), or presumably, due to effective innate immune responses, although this remains conjectural. Thus, the characteristics that influence a state of natural resistance at a young age seem to be lost -at least partly -with aging, but it is also likely that they might still prevail in certain individuals for reasons that remain unknown.

Arguments supporting a natural resistance to developing COVID-19 have also been provided by several studies assessing SARS-CoV2-specific seroprevalence in different populations; results show that there are discrepancies between mathematical models of infection and the measured seroprevalence of antibodies in human circulation.

Specifically, Sweden reported a seroprevalence of 7.3% in the Stockholm area in April 2020 despite mathematical models predicting an infection rate of 20-25% [24] . An interesting case study is that of the Diamond Princess cruise ship that in February 2020 was confronted with a COVID-19 outbreak while in the western Pacific ocean, reporting half of the global COVID-19 cases at that time --excepting China [25, 26] . The infection rates on the cruise ship were mathematically projected to be higher than those occurring in open spaces, since complete isolation was not possible, and the members of the crew were still exposed to the virus. Different studies have estimated the reproducibility rate (R 0 ) during the outbreak period in the ship to be between 5.71 and 14.8 [25, 26] , which suggests that the number exposed individuals was higher than those actually infected. Subsequently, in contrast to the officially reported 712 individuals with PCR-positive results for COVID-19, one study reported a calculation in J o u r n a l P r e -p r o o f Journal Pre-proof which this number should have been at least 1000 [26] . While sensitivity issues with the diagnostic tests may explain some of the missing cases, the large difference reported is unlikely to be due to this sole cause. This discrepancy likely includes a significant number of individuals that encountered the virus but, presumably, were naturally resistant.

Notwithstanding the likely existence of natural resistance in certain populations, there are large differences in COVID-19-related morbidity and mortality rates between countries [27]. After the first wave of the pandemic, studies from India reported 11 million COVID-19 cases and 155,000 deaths as of February 26th, 2021 [28] . Later, during the months of March to May 2021, a second wave of the pandemic was recorded due to the SARS-CoV2 delta variant of concern, despite high seropositivity for individuals with COVID-19 in major urban areas: e.g. New Delhi showed 56% Similarly, a lower case-fatality rate has been observed in India compared to other countries [29] . Thus, India has demonstrated relatively low mortality rates despite its high population density, lack of restrictive measurements, and suboptimal health infrastructure. Notably, in the state of Karnataka in India, 91% of the reported COVID-19 infections were asymptomatic [30] .

On the one hand, the contrast in morbidity and mortality is remarkable between India, developing countries in Sub-Saharan Africa, and developing countries in Latin America (such as Peru, Brazil, and Mexico). The demographic structure of these developing countries' populations, with high percentages of young individuals in all these geographical locations, is unlikely to explain the differences in the burden of COVID-19 when comparing India, Sub-Saharan Africa, and Latin America. On the other hand, it has been hypothesized that high infectious pressure in India and Sub-Saharan Africa might contribute, at least in part, to a certain degree of natural resistance to J o u r n a l P r e -p r o o f Journal Pre-proof pathogens [31] . The large pathogen burden in developing countries [32] constantly engages the innate immune system, protecting individuals against infections, and even leading to evolutionary adaptations in the long term, akin to the hygiene hypothesis [31] .

In line with this, an example of possible large-scale natural resistance is reflected in the COVID-19 pandemic in the sub-Saharan Africa. While sub-Saharan countries might be expected to experience rapid expansion of the pandemic and considerable numbers of victims (due to the absence of a strong healthcare infrastructure and limited restrictive measures adopted), the incidence and mortality of COVID-19 have been much lower than in other regions of the world in which countries harbor more prepared and advanced healthcare systems and stronger containment measures [28] . This difference might be in part due to factors such as the relatively low age of the population in Africa [33] , but might also suggest a high degree of natural resistance in the population,

although this remains to be tested. Of note, a recent study compared the prevalence of cross-reactive antibodies against SARS-CoV-2 in COVID-19 patient samples obtained prior to the full-blown start of the pandemic from sub-Saharan Africa versus the USA; seroprevalence was 6-8 times higher in plasma samples from Tanzania and Zambia than in those from the USA [34] . It is reasonable to speculate that these cross-reactive antibodies arose in response to previous contacts with other coronaviruses present in the environment in sub-Saharan countries, and that they induced cross-protection against SARS-CoV-2 infection (and thus natural resistance) in African populations. We argue that collectively, these studies suggest that natural resistance to SARS-CoV-2 can be present in human populations and may impact the outcomes of the pandemic for different age groups and countries.

One important aspect to consider is the fact that two types of responses might protect a host from the deleterious effects of an infection: on the one hand, there are resistance mechanisms that aim to eliminate a microorganism, and on the other hand, there are tolerance mechanisms that aim to avoid collateral damage due to J o u r n a l P r e -p r o o f inflammation or over-activation of the immune response. Indeed, disease tolerance represents a crucial component for host defense, ensuring that the collateral damage that could be induced by an effective immune system is limited and does not place the host in danger [35] . A proper balance between resistance and tolerance is crucial for the most effective strategy of survival during infections [36] , including for COVID-19, in which overwhelming inflammation is dangerous in critically-ill patients [37] .

An important environmental process that can provide natural resistance against viral infections, even if only for a relatively short period, is viral interference. This is the process in which previous exposure of cells to another virus induces inhibition of viral reproduction [38, 39] . eggs exposed to IAV produced a factor, "interferon", that when transferred to new eggs could prevent infection with the virus [40] . Recently, interference between rhinoviruses and SARS-CoV-2 was also demonstrated, with rhinoviruses blocking the replication of SARS-CoV-2 in human epithelial cells [41] . In addition to IFN-dependent mechanisms, other mechanisms might also play a role in viral interference: for instance, certain studies have suggested that there is competition for receptors used for viral entry, and furthermore, that the occupancy or down-modulation of cellular receptors for certain viruses might also be involved [42] . In addition, recent epidemiological data also suggest that viral interference exists between IAV and coronaviruses [43] . We therefore posit that a higher circulation/dissemination of different viruses in India or sub-Saharan Africa might contribute to explain the lower susceptibility to SARS-CoV-2 infections in these populations compared to Europe and the Americas, for which the process of viral interference might also play an important role.

As alluded to above, natural resistance against an infection might also be afforded by pre-existing adaptive immunity. For instance, approximately half of individuals not exposed to SARS-CoV harbor reactive CD4 + T cells against SARS-CoV-2 in peripheral blood [44] . Moreover, prexisting memory CD4 + T cells reactive to SARS-CoV-2 and with comparable affinity to the common cold human coronaviruses, i.e., OC43, NL63, HKU1 J o u r n a l P r e -p r o o f and 229E, have been reported in human unexposed individuals; this finding might support the idea that exposure to common cold viruses might result in some degree of protection against SARS-CoV-2, although this remains to be thoroughly tested [45] . In addition, pre-existent polymerase-specific CD4 + T cells have been described in persistently seronegative healthcare workers, which might presumably lead to abortive infection and protect these individuals from COVID-19 [46] . However, there are other studies suggesting that cross-reactive antibodies and CD4 + T cells do not contribute to the clearance of SARS-CoV-2 infections. Specifically, one study reported that infections with SARS-CoV-2 increased the circulating titers of seasonal human coronavirus antibodies but did not neutralize SARS-CoV-2 virion particles [47] . Another group measured the anti-SARS-CoV-2 neutralizing activity in sera obtained from individials infected with seasonal coronavirus prior to the pandemic and did not detect any cross-realtive neutralizing activity against SARS-Cov2, suggesting that the crossreactive coronavirus antibodies may have not been neutralizing [48] . However, most of these studies have been conducted in small samples from urban settlements in highly developed cities from the USA or Europe, where presumably, individuals maintain high hygiene standards and are exposed to low pathogenic burdens, including coronaviruses. Evidently, such studies would benefit from the inclusion of larger and more diverse population samples, and from the comparison of the neutralization potential of the sera obtained from individuals living under different socioeconomic conditions and environments. Finally, one aspect that deserves attention in future studies is that of potentially protective T-regulatory cell (Treg) effects during SARS-CoV2 infections; these populations, by inhibiting hyperinflammation and ensuring a tolerant phenotype, might be more relevant than previously anticipated [49] .

There is another potential immune mechanism via which natural resistance to SARS-CoV-2 might be induced: the presence of effective innate immune responses, which might eliminate the virus before the engagement of adaptive immunity is needed.

Specififcally, an innate immunity profile characterized by high cytokine production upon stimulation with pathogens has been described to be associated with early clearance/natural resistance; for example, this has been described in detail for tuberculosis (TB) [50] . Indeed, stronger heterologous cytokine responses upon J o u r n a l P r e -p r o o f stimulation with bacterial stimuli were reported in an Indonesian population in which close contacts exhibited natural resistance to TB [51] , compared with a population susceptible to the disease. This suggested that, for various pathogen scenarios, the increased capacity of innate immune cells to respond against infection by producing cytokines upon stimulation, can contribute to establishing natural resistance in some individuals.

Of note, the quality and nature of innate immune responses is definitely not static and should not be ignored: for instance, Bacillus Calmette-Guérin (BCG) vaccination not only provides some protection against TB, but it can also enhance innate immunity, as evidenced by higher cytokine production upon stimulation of circulating monocytes with non-mycobacterial stimuli compared to controls [52] . The latter process, whereby vaccines or certain infections induce long-term improvement of innate immune responses, also termed trained immunity, is mediated through long-lasting epigenetic and metabolic rewiring of myeloid cells [53, 54] . Induction of trained immunity by liveattenuated vaccines such as BCG, measles-mumps-rubella (MMR) or oral polio (OPV)vaccines has been suggested as a potential approach for eliciting protection against COVID-19 because it increases innate anti-viral responses early during an infection; indeed, several clinical trials are investigating this hypothesis [55, 56] . A recently published initial observational study suggested an association betwen BCG vaccination with less COVID-19 symptoms in a population of elderly individuals from Greece [57] , while a case-control study investigated the impact of MMR on immunity, and reported a significant protection against COVID-19 [58] , supporting the hypothesis that certain live attenuated vaccines may induce non-specific protection against COVID-19. Moreover, abundant exposure to environmental microorganisms might also play a role in inducing trained immunity, and thereby, to enhancing putative natural resistance to pathogens such as SARS-CoV-2. Collectively, we argue that these studies suggest multiple mechanisms that might be implicated in inducing a state of natural resistance against infections in humans, including with SARS-CoV-2: these may consist of viral interference as well as heterologous innate and adaptive immune processes.

Thus, thorough and robust preclinical and clinical assessments are eagerly awaited to test these hypotheses (Key Figure, Figure 3 ).

Understanding the entire clinical spectrum of an infection is crucial to elucidating its impact at the individual as well as population levels. Knowing the extent to which an infection --and especially one that can intigate a pandemic --can cause severe, mild, or asymptomatic disease, is also important for deciding public health measures to limit its burden. Similarly, identifying individuals within the population who are naturally resistant against a particular infection is important for understanding host defense, and to inform novel putative strategies for prevention and therapy.

Presently, available data regarding natural resistance to COVID-19 is accumulating, albeit scattered. Efforts should be made on several fronts to understand these data more comprehensively. Pandemics are not exceptions in human history. The emergence of new pathogens or new variants of old pathogens can lead to global spread of infections in the absence of immunological memory. While the development of classical types of vaccines should and will remain a fundamental tool for the prevention of future pandemics, the design, development, testing, production, and distribution of future vaccines will need at least 12 to 24 months --even in the most optimistic scenarios. In this initial phase of a pandemic, the spread of the infection can have dire consequences for global health and economy, as has been witnessed for COVID-19. It is therefore crucial that we become better prepared for a future epidemic/pandemic, not if, but when. We propose the development of parallel preventive strategies to boost general natural resistance of a host (until specific vaccines can be developed) will be crucial. One such strategy might be the development of vaccines that can stimulate heterologous/trained immunity responses, which could induce broad (partial) protection against multiple pathogens (Figure 4 ).

One might also envision testing additional live attenuated vaccines to induce trained immunity, and/or developing novel adjuvants with such properties. Indeed, in addition to previously studied live attenuated vaccines such as BCG, MMR, and OPV, recent work testing the AS03-adjuvanted IAV vaccine in humans also demonstrated that such vaccinations could stimulate epigenetic changes in myeloid cells which persisted for several weeks to months, and conferred heightened protection against unrelated J o u r n a l P r e -p r o o f viruses such as dengue and zika [59] . Understanding natural resistance for COVID-19 in years to come may thus represent a vital step for future pandemic preparedness.

There are more than 1400 species of bats, representing more than 20% of the world's mammalian species. Bats act as reservoirs of multiple human pathogens, including fearsome viruses such as rabies, Ebola, Marburg, Nipah, MERS-CoV, SARS-CoV, or SARS-CoV-2. Surprisingly, these viruses are well-tolerated by bats and do not cause pathology.

Why are bats able to tolerate infections which are deadly for other mammals? There are many details of bat immunology that remain unknown, but through several adaptations, the key seems to lie in their ability to mount a mild immune response and avoid the excessive inflammatory response that could lead to tissue damage and organ failure. First, as flying mammals, bats can increase their metabolic activity rates to levels twice as high as those found in rodents when running [60] . Second, the increased metabolic rate and high body temperature supports an immune response that controls infections, in a manner comparable to the rise in metabolic activity and the development of fever in humans affected by infection [61] . Third, several bat species express IFNα constitutively, even in the absence of viral infections [62] , which helps limit the spread of viruses in the bat without developing an exacerbated systemic immune response. Combined with a reduced ability to detect viral DNA and batspecific inflammasome adaptations (lack of inflammatory genes, low function of NLRP3 inflammasome) [49, 50] , constitutive IFNα expression helps to maintain low production of inflammatory cytokines, limiting the development of inflammatory responses that could cause tissue damage.

J o u r n a l P r e -p r o o f Box 2: Host-dependent mechanisms associated with resistance to pathogens Natural resistance: the infectious agent is unable to infect the host; this may be due to genetic variants in genes important for entry mechanisms, (for example, the absence of a receptor on a host cell that is key for viral entry) or by the rapid elimination of the pathogen by host resistance mechanisms. Such rapid clearance may be accomplished by potent components of our rapid-acting innate immune system, by effective heterologous cross-reactive immunity by natural antibodies, by cross-reactive T-cells, or by the synergistic actions of such mechanisms [63] . Under such circumstances, the disease process stops within a few days after infection, without needing to engage adaptive immune mechanisms.

Asymptomatic infection: the host goes through the entire cascade of interactions between the infectious agent and host defense mechanisms. In this situation, host defense mechanisms can mount a response strong enough to control the pathogen which will be ultimately eliminated or tolerated (e.g., HIV-1-infected long-term nonprogressors). Both situations avoid an immunopathological inflammatory response. In these individuals, adaptive immunity will ensue and long-term immunological memory may be induced. Individuals can be classified according to their degree of susceptibility, from higher to lower, and resistant individuals. These profiles are defined by the inflammatory responses developed in response to infection, IFN release, and antibody production [3] . Potent IFN responses and lower inflammatory responses are generally linked to better prognosis during viral infections (i.e. SARS-CoV2), as they are associated with enhanced early responses that prevent replication and limit viral invasiveness [66] . The specific mechanisms leading to the development of natural resistance to COVID-19 are yet to be elucidated but most likely include genetic resistance, the developemt of J o u r n a l P r e -p r o o f Cross-reactive antibodies: Antibodies recognizing antigens other than the one they are originally generated against.

Hygiene hypothesis: proposes that childhood exposure to germs and certain infections can enable the immune system to develop a balanced response to infections and allergens.

Morbidity: Number of people who become ill in a given place and time period relative to the total population. Mortality: Number of people who die in a given place and time period relative to the total population.

Reproducibility rate (R 0 ): Number of individuals that one infected person will pass on a virus to, on average.

Percentage of people in a population, harboring antibodies against a specific antigen in serum; indication that they have been exposed to a specific infectious organism.

Trained immunity: Long-term functional reprogramming of innate immune cells; evoked by exogenous or endogenous insults; leads to an altered response towards a second challenge after the return to a non-activated state. Natural resistance against pathogens is described for many infections. There is no reason to believe that this might be different for SARS-CoV-2 infections.

-There are discrepancies between different SARS-CoV-2 infection models and the seroprevalence of antibodies in circulation.

-Differences in the morbidity and mortality between countries suggest that genetic and environmental differences may influence host defense against SARS-CoV-2

infection.

-Studies in children, adults residing in confined environments, as well as from individuals residing in different geographical locations, suggest that natural resistance against SARS-CoV-2 is present in human populations, and may differentially impact the course of the pandemic for such populations.

-Crucial for host survival is the balance between resistance mechanisms aiming to eliminate host pathogens and tolerance mechanisms aiming to avoid collateral damage induced by inflammatory processes.

J o u r n a l P r e -p r o o f

Bats and coronaviruses. , Viruses, 11

Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. , The Lancet

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis

Early clearance of Mycobacterium tuberculosis: a new frontier in prevention

Human genetics and malaria resistance

Protection afforded by sickle-cell trait against subtertian malareal infection

World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb

Detecting recent positive selection in the human genome from haplotype structure

Resistance to HIV-1 infection among persistently seronegative prostitutes in

Long-term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation

The COVID-19 pandemic: a global health crisis

A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections

A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans

Variation in the human immune system is largely driven by non-heritable influences

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Coronavirus Disease 2019 in Children -United States

Susceptibility to SARS-CoV-2 Infection among Children and Adolescents Compared with Adults: A Systematic Review and Meta-Analysis

Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany

SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study

Four months into the COVID-19 pandemic, Sweden's prized herd immunity is nowhere in sight

COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures

The Bayesian Susceptible-Exposed-Infected-Recovered model for the outbreak of COVID-19 on the Diamond Princess Cruise Ship

A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Will India's devastating COVID-19 surge provide data that clear up its death 'paradox'? Science (80-. )

Descriptive epidemiology of SARS-CoV-2 infection in Karnataka state, South India: Transmission dynamics of symptomatic vs. asymptomatic infections

Impact of Historic Migrations and Evolutionary Processes on Human Immunity

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study

Africa's low COVID-19 mortality rate: A paradox?

High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

Disease tolerance as a defense strategy

Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases

Targeting inflammation and cytokine storm in COVID-19

Viral Interference: The Case of Influenza Viruses

Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China

Virus interference. II. Some properties of interferon

Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology

Co-infection, super-infection and viral interference in HIV

Virus-virus interactions impact the population dynamics of influenza and the common cold

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection

Role of Metabolism in the Immunobiology of Regulatory T Cells

BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for nextgeneration vaccines

Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia

Early Clearance of Mycobacterium tuberculosis Is Associated With Increased Innate Immune Responses

Advances in understanding molecular regulation of innate immune memory

Trained Immunity: Reprogramming Innate Immunity in Health and Disease

Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

ACTIVATE-2: A DOUBLE-BLIND RANDOMIZED TRIAL OF BCG VACCINATION AGAINST COVID19 IN INDIVIDUALS AT RISK

A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children

The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination

Bat flight and zoonotic viruses

Contraction of the type i IFN locus and unusual constitutive expression of IFN-α in bats

2020) T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

Human genetic susceptibility to intracellular pathogens

Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

The work of M.G.N. was supported by an ERC Advanced Grant (#833247), a Spinoza Grant of the Netherlands Organization for Scientific Research, and a COVID19 FastGrant. R.v.C was supported by National Institute of Health (R01AI145781). J.D.-A. was supported by a Veni grant of The Netherlands Organization for Scientific Research (09150161910024). The work in Bali Pulendran's lab was supported by grants from the National Institutes of Health (U19AI090023, R01AI048638, R01 DK057665, U19AI057266), the Bill and Melinda Gates Foundation, and Open Source Philanthropy.